Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic Escherichia coli induced hemolytic uremic syndrome

References

• Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol. 2010;25(11):2231–2240.
   PubMed Web of Science ®Google Scholar
• Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23(10):1749–1760.
   PubMed Web of Science ®Google Scholar
• Hahn JS, Havens PL, Higgins JJ, et al. Neurological complications of hemolytic-uremic syndrome. J Child Neurol. 1989;4(2):108–113.
   PubMed Web of Science ®Google Scholar
• Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr. 1994;125(4):511–518.
   PubMed Web of Science ®Google Scholar
• Kamioka I, Yoshiya K, Satomura K, et al. Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int. 2008;50(4):441–446.
   PubMed Web of Science ®Google Scholar
• Buteau C, Proulx F, Chaibou M, et al. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J. 2000;19:642–647.
   PubMed Web of Science ®Google Scholar
• Shiraishi M, Ichiyama T, Matsushige T, et al. Soluble tumor necrosis factor receptor 1 and tissue inhibitor of metalloproteinase-1 in hemolytic uremic syndrome with encephalopathy. J Neuroimmunol. 2008;196(1–2):147–152.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Kuroda M, Sakashita N, et al. Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2012;60(3):694–700.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Inoue N, Kuroda M, et al. Angiopoietin-1 and -2 as markers for disease severity in hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli. Clin Exp Nephrol. 2017;21(1):76–82.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Kuroda M, Inoue N, et al. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014;66(1):1–6.
   PubMed Web of Science ®Google Scholar
• Khan S. IGFBP-2 signaling in the brain: from brain development to higher order brain functions. Front Endocrinol (Lausanne). 2019;10:822.
   PubMed Web of Science ®Google Scholar
• Russo VC, Azar WJ, Yau SW, et al. IGFBP-2: the dark horse in metabolism and cancer. Cytokine Growth Factor Rev. 2015;26(3):329–346.
   PubMed Web of Science ®Google Scholar
• Neidel J. Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2001;19:81–84.
   PubMed Web of Science ®Google Scholar
• Ding H, Kharboutli M, Saxena R, et al. Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. Clin Exp Immunol. 2016;184(1):11–18.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ding HH, Kharboutli M, et al. Axl, ferritin, insulin-like growth factor binding protein 2, and tumor necrosis factor receptor type II as biomarkers in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68(9):1303–1309.
   PubMed Web of Science ®Google Scholar
• Narayanan RP, Fu B, Heald AH, et al. IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes. Endocr Connect. 2012;1(2):95–102.
   PubMed Web of Science ®Google Scholar
• Buder K, Latal B, Nef S, et al. Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome. Pediatr Nephrol. 2015;30(3):503–513.
   PubMed Web of Science ®Google Scholar
• Fujinaka H, Katsuyama K, Yamamoto K, et al. Expression and localization of insulin-like growth factor binding proteins in normal and proteinuric kidney glomeruli. Nephrology (Carlton). 2010;15(7):700–709.
   PubMed Web of Science ®Google Scholar
• Mohammed JA, Mok AY, Parbtani A, et al. Increased expression of insulin-like growth factors in progressive glomerulonephritis of the MRL/lpr mouse. Lupus. 2003;12(8):584–590.
   PubMed Web of Science ®Google Scholar
• Takanashi J, Taneichi H, Misaki T, et al. Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology. 2014;82(7):564–572.
   PubMed Web of Science ®Google Scholar
• Benbassat CA, Lazarus DD, Cichy SB, et al. Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro. Horm Metab Res. 1999;31(2–3):209–215.
   PubMed Web of Science ®Google Scholar
• Lang CH, Pollard V, Fan J, et al. Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. Am J Physiol. 1997;273(1 Pt 2):R371–R378.
   PubMedGoogle Scholar
• Wood TL, O'Donnell SL, Levison SW. Cytokines regulate IGF binding proteins in the CNS. Prog Growth Factor Res. 1995;6(2–4):181–187.
   PubMedGoogle Scholar
• Kuroda M, Shimizu M, Inoue N, et al. Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome. Neurochem Int. 2015;85–86:24–30.
   PubMed Web of Science ®Google Scholar
• Chesik D, De Keyser J, Wilczak N. Insulin-like growth factor binding protein-2 as a regulator of IGF actions in CNS: implications in multiple sclerosis. Cytokine Growth Factor Rev. 2007;18(3–4):267–278.
   PubMed Web of Science ®Google Scholar
• Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol. 1999;57(6):563–581.
   PubMed Web of Science ®Google Scholar
• Klempt ND, Klempt M, Gunn AJ, et al. Expression of insulin-like growth factor-binding protein 2 (IGF-BP 2) following transient hypoxia-ischemia in the infant rat brain. Brain Res Mol Brain Res. 1992;15(1–2):55–61.
   PubMedGoogle Scholar
• Baker NL, Carlo Russo V, Bernard O, et al. Interactions between bcl-2 and the IGF system control apoptosis in the developing mouse brain. Brain Res Dev Brain Res. 1999;118(1–2):109–118.
   PubMedGoogle Scholar